Who Owns BGLC?

BioNexus Gene Lab Corp. — Institutional Ownership & 13F Holdings

$2.44

-0.13 (-4.88%)

Market Cap

$4.0M

Shares Outstanding

Institutional Holders

4

Total Inst. Value

$37K

% of Float Held

QoQ Holder Change

+1

Institutional data as of Q1 2025

New Positions

4

Closed Positions

0

Increased

0

Decreased

0

Institutional Ownership Trend

Top 10 Institutional Holders(Q1 2025)

#FundValueShares
1CITADEL ADVISORS LLCNew$23K98,768
2TWO SIGMA INVESTMENTS, LPNew$8K35,532
3GEODE CAPITAL MANAGEMENT, LLCNew$5K23,681
4UBS Group AGNew$14

Biggest Buyers & Sellers This Quarter

Top Buyers

FundShares AddedValue
CITADEL ADVISORS LLCNew+99K$23K
TWO SIGMA INVESTMENTS, LPNew+36K$8K
GEODE CAPITAL MANAGEMENT, LLCNew+24K$5K
UBS Group AGNew+4$1

Top Sellers

FundShares RemovedValue

Related Stocks

Frequently Asked Questions

How many institutional investors hold BGLC?

As of Q1 2025, 4 institutional investors report holding BGLC (BioNexus Gene Lab Corp.) in their 13F filings.

Which hedge fund owns the most BGLC?

The largest institutional holder of BGLC is CITADEL ADVISORS LLC with $23K in shares.

Are institutions buying or selling BGLC?

This quarter, 4 institutions opened new positions in BGLC and 0 closed their positions.

What is 13F institutional ownership?

SEC Form 13F is a quarterly report filed by institutional investment managers with over $100M in qualifying assets. It discloses their US equity holdings, providing transparency into what the largest investors are buying and selling.

How often is institutional ownership data updated?

13F filings are due 45 days after each calendar quarter end (May 15, Aug 14, Nov 14, Feb 14). Data is updated on HedgeTrace as new filings are processed.